Full Papers
Clinical impact of anti-SSA antigenic specificity on disease activity and patient-reported outcomes in primary Sjögren’s disease: a real-life cohort study
S. Fonzetti1, G. La Rocca2, G. Fulvio3, B. Dei4, C. Porciani5, F. Ferro6, P. Migliorini7, M. Mosca8, C. Baldini9
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Clinical Immunology Unit, Department of Internal Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Clinical Immunology Unit, Department of Internal Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. chiara.baldini74@gmail.com
CER19492
2025 Vol.43, N°12
PI 2209, PF 2216
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 41410582 [PubMed]
Received: 04/11/2025
Accepted : 10/12/2025
In Press: 18/12/2025
Published: 18/12/2025
Abstract
OBJECTIVES:
Anti-Ro/SSA antibodies are a hallmark of Sjögren’s disease (SjD), yet the clinical implications of distinct antigenic targets remain insufficiently defined. We aimed to determine whether specific anti-SSA antigenic profiles-isolated anti-Ro52, isolated anti-Ro60, double anti-Ro52/anti-Ro60, or triple anti-Ro52/anti-Ro60/anti-La/SSB positivity, are associated with distinct systemic, serological, and patient-reported phenotypes in real-life clinical practice.
METHODS:
We analysed 279 anti-SSA-positive SjD patients fulfilling 2016 ACR/EULAR criteria. Participants were stratified into the four serological subsets and compared for demographics, cumulative ESSDAI domains, systemic activity (ESSDAI), immunologic markers (IgG, C3, C4), and patient-reported outcomes (ESSPRI and subdomains) at study entry. Group comparisons used ANOVA/ANCOVA and Kruskal-Wallis tests, with modified Poisson regression for adjusted prevalence ratios and general linear models for adjusted means.
RESULTS:
Triple-positive patients displayed the highest systemic inflammatory activity (ESSDAI median 3 [IQR 1–6]) and IgG levels (1497 [1180–1790] mg/dL; p<0.001), enriched for haematologic, lymphoid, glandular and biological domains. In contrast, isolated anti-Ro60 patients showed the mildest systemic activity (ESSDAI 0 [0–0]) yet the highest patient-reported burden (ESSPRI 6.08 [0.52]; p<0.01), revealing a marked dissociation between objective inflammation and symptoms. Isolated anti-Ro52 displayed the broadest and most heterogeneous phenotype, and older age at diagnosis. In adjusted analyses, only triple-positive patients remained independently associated with increased systemic activity and B-cell hyperactivity (all p<0.05). Symptom measures showed the opposite gradient: isolated anti-Ro52 and anti-Ro60 subsets had the highest adjusted ESSPRI, pain, and fatigue scores, whereas double- and triple-positive patients reported substantially fewer symptoms. When stratified by combined ESSDAI/ESSPRI scores, low-activity/high-symptom cases predominated and were enriched among isolated anti-Ro52 and anti-Ro60 patients.
CONCLUSIONS:
Anti-SSA antigenic specificity delineates biologically and clinically distinct phenotypes within SjD. These data support serology-informed, multidimensional disease stratification as a foundation for precision-targeted management in SjD.
